Talk:Tolvaptan

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Stub	This article has been rated as Stub-class on Wikipedia's content assessment scale.
???	This article has not yet received a rating on the project's importance scale.

JAMA

Oops, not quite effective in heart failure, but some short-term benefits observed. JFW | T@lk 14:27, 25 March 2007 (UTC)[reply]

If anyone knows of a study, in the US, for this drug---please send information to me! I have SIADH and my nails are disappearing due to long term use of Demeclocycline. I really want to be switched to this new med.

My email is ashlandsarah@gmail.com

Thank you67.42.178.80 (talk) 01:54, 25 March 2008 (UTC)[reply]

Racemic drug

Tolvaptan is a racemic small molecule drug (Molecular Weight of 448.9 g.mol-1) and is a lipophilic drug, is essentially insoluble in water, and has fair oral absorption (>40% bioavailable). Tolvaptan hsa a plasma half-life of around 12 hours, a volume of distribution of 3L/kg, and has high plasma protein binding at 99%. Tolvaptan is extensively metabolised by 3A4, and therefore has many concommitent interactions with 3A4 substrates, inhibitors and inducers. Reportedly, Tolvaptan metabolites show no appreciable pharmacology against the vasopressin receptors. Interestingly, Tolvaptan is a racemic drug, with the two enantiomers showing differing PK/PD. Typical daily dosing is 30mg (or ~67µmol), or 60mg if insufficient efficacy is observed.

The compound shown is not Tolvaptan based on this information